ASGCT 2026: Tenaya Therapeutics today presented interim clinical data for its gene therapy for patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by PKP2 mutations
CEO Faraz Ali walks us through the data, which included six patients, and sets the table for a future update on a gene therapy program for hypertrophic cardiomyopathy that will be announced before the end of the quarter. Coverage brought to you by
7 hours ago
ASGCT 2026: Aurion Biotech is developing an off the shelf cell therapy solution for Corneal endothelial disease, a type of blindness, where only donor transplants are currently available to some
Founder, CSO & CEO Arnaud Lacoste describes the treatment, which is derived from one donor and can treat up to 1,000 patients, and comes in a solution containing a rho-kinase inhibitor. It is currently in a U.S. pivotal study. Coverage brought to you by
8 hours ago
ASGCT 2026: Benitec Biopharma presented a clinical update of its lead DNA-directed RNA interference program targeting Oculopharyngeal Muscular Dystrophy (OPMD)
Executive Chair & CEO Jerel Banks describes how Benitec is programing the body to create its own internal continuous RNAi factory to treat this disease. With this clinical data in hand, Benitec plans to meet with FDA about the design of a pivotal trial. Coverage brought to you by
11 hours ago
ASGCT 2026: Tevard Biosciences' suppressor tRNA programs could have the potential to treat genetic diseases more broadly than the way we traditionally think of drug development
Co-Founder and CEO Daniel Fischer describes how Tevard is harnessing tRNA for drug development against muscular dystrophies, cardiomyopathies, and epilepsies. The company could run basket trials and possibly earn flexible labels because these tRNAs are targeting a class of mutations rather than specific genes. Coverage brought to you by
1 day ago
ASGCT 2026: SonoThera has a unique ultrasound-mediated nonviral approach to gene therapy. It has plans to be in the clinic for DMD next year
Co-Founder & CEO Ken Greenberg describes the idea around and advantages of this approach, including no limitation on cargo size. He describes how it would work for DMD, and what other conditions and uses they are thinking of next. Coverage brought to you by
1 day ago
ASGCT 2026: Michael Torres isn't slowing down after selling his antibody-drug conjugate company to Eli Lilly. Here's his gene therapy play
He describes the work he is involved in with ARTAN Bio, which has a tRNA suppressors approach to diseases of aging and logevity. Plus, a unique crypto financing angle to this story. Coverage brought to you by
1 day ago
.png){kind=logo}
